Growth retardation in pediatric inflammatory bowel diseases – pathogenesis and treatment

Zaburzenia wzrastania u dzieci z nieswoistymi zapaleniami jelit – patogeneza oraz możliwości leczenia

Tomasz Pytrus, Barbara Iwańczak

Department of Pediatrics, Gastroenterology and Nutrition, Medical University of Wroclaw, Poland

Abstract

Growth retardation is a common complication in children with inflammatory bowel disease. A combination of the following factors results in growth retardation: insufficient food intake, malabsorption, increased catabolism, disease activity, disease extension, complications of disease and the side-effects of treatment. Clinical response to therapy is associated with an improvement in linear growth.

Introduction

Inflammatory bowel disease (IBD) onset can occur at any age, but in 25% of patients the disease begins during infancy. The clinical picture of these diseases in children differs from that observed in adults. Inflammatory bowel diseases more frequently have an aggressive and complicated course in the pediatric population. There is a higher tendency for strictures and fissure formation, especially in Crohn’s disease, which requires surgical intervention. In ulcerative colitis the extent of the disease is greater than in adults and due to earlier severe exacerbations the inevitability of the surgery emerges not rarely. These differences gave the rationale for the modification of the Montreal Classification of inflammatory bowel diseases and for the elaboration of the new Paris Classification, which takes into consideration the issues specific for children [1-4]. Of great importance is the fact, which particularly distinguishes children with inflammatory bowel disease, that the disease appears within the period of intense development, influencing its rate and often causing its retardation or even inhibition. This results in growth retardation and in smaller final height, malnutrition, pubertal delay and bone mineralization disturbances in the form of osteopenia and osteoporosis. Growth retardation is considered to be a particularly important complication of the disease, which on one hand points to the high disease activity, while on the other hand, an improvement of the growth rate may be an advantageous sign of the efficacy of therapy. In this period of life growth is one of the important parameters enabling proper identification with the peer group and therefore its retardation has an enormous negative impact on the psychosocial development and on the smooth transition from childhood to maturity. All those elements cause the deterioration of the life quality. The growth process may be defined either as the
maximal height reached at its finishing point or it can be described as the rate of growth or high velocity (HV). In analysis of these processes we are obliged to consider population differences, ethnic and gender (menarche in girls) differences, and to take into account the height of parents and other genetic circumstances.

**Etiology and frequency of growth disturbances in children with inflammatory bowel disease**

Growth impairment in children with inflammatory bowel disease is a result of malnutrition, which in turn is related to the disturbance of intestinal absorption, restrictions in the diet of ill children and of increased metabolic requirements. The decrease of growth rate is deepened by the detrimental influence of pro-inflammatory cytokines (e.g. IL-6, TNF-α) and by treatment with corticosteroids [5, 6]. Growth retardation is significantly more frequently observed in children with Crohn’s disease than in those with ulcerative colitis. The presence of NOD2/CARD15 mutation in this group of patients is linked to the ileo-colonic localization of the disease with more aggressive course, which also may result in malnutrition and retardation or arrest of growth. In patients with NOD2/CARD15 mutation the risk of surgery is 39.5% in comparison to 12.8% in patients free of this defect. In the study of Wine et al. it was observed that the presence of NOD2/CARD15 mutation carries a risk of a more severe course of the disease, which in turn may slow down the growth. However, no direct correlation of this mutation with growth retardation has been demonstrated [7]. A similar role is ascribed to IBD5 gene polymorphism, presence of which is associated with growth retardation. In 46% of children with Crohn’s disease retarded growth is present before any intestinal symptoms of the disease and only 12% of these children present a proper growth rate at the time of diagnosis. Particularly significant growth retardation is observed when the disease is localized mainly in the small intestine, since up to 19% of these children reach the final height eight centimeters smaller than expected [4]. In the group of children with ulcerative colitis only 3-10% demonstrate a decreased growth rate at diagnosis [4, 9]. Sometimes at the time of diagnosis not only growth retardation and sexual maturation retardation are observed, but also chronic, serious disturbances of bone mineralization in the form of severe osteoporosis, which are the first symptoms of IBD, are present as well [10]. It has been demonstrated that, among others, growth retardation, body mass deficiency, intestinal strictures, young age, male sex and the presence of extra-intestinal symptoms of the disease are factors pointing to an aggressive and complicated course of the disease [11].

Studies on growth and development rate are very difficult and require proper methodology and sophisticated measurement equipment [12]. They are based on anthropometric measurements, calorimetric studies, bio-impedance, isotope studies, radiologic imaging and laboratory studies. It seems that the problem of disturbances of growth due to its interdisciplinary character require collaboration between gastroenterologists and other specialists such as endocrinologists, andrologists and anthropologists, as well as experts from basic sciences. A dietician who has proper experience in pediatric nutrition is also an indispensable member of the therapeutic team [13]. Management of children with inflammatory bowel disease in whom the disease appeared during the period of physiological growth and maturation always require meticulous supervision of growth.

**Pathomechanism of growth disturbances in children with inflammatory bowel disease**

Many different mechanisms, which frequently occur concomitantly and overlap, should be taken into account in the analysis of pathogenetic factors causing growth disturbances. Hartman et al. in a work discussing the nutritional state and methods of nutritional treatment in inflammatory bowel diseases presented causes of malnutrition and pathophysiology of growth retardation taking into account various etiopathogeneses and mechanisms [14]. Pathogenesis of growth disturbances is presented in Tables I and II [14].

**Hormonal and inflammatory factors**

Inadequate secretion or deficiency of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), GH/IGF-1 axis disturbances as well as tissue resistance to the action of those factors are the main features of hormonal disturbances in children with inflammatory bowel disease [15, 16]. Bioavailability of IGF-1 (somatedin C) depends on its free fraction and on its serum carriers, namely binding proteins (IGFBPs: IGFBP-1 to IGFBP-6). Binding proteins demonstrate various affinity to IGF-1 and the inflammatory process, and nutritional and caloric restrictions may lead to deficiency of some of them. Growth hormone is responsible for the induction of the precursor cells in the growth plate and on the other hand IGF-1 stimulates differentiation of chondrocytes. The protein STAT5, which is an activator and a factor responsible for transcription and in consequence for GH-dependent growth, is of fundamental importance. STAT5 exists in two forms (A and B) and the STAT5B form participates in growth regulation. The mechanism of inhibition of growth hormone’s biological effect consists
on the one hand of the decrease of the number of specific receptors (downregulation) and on the other of the increase of suppressor protein levels (upregulation). It happens that children with inflammatory bowel disease, particularly those with Crohn’s disease, in whom symptoms of the disease are untypical, are chronically treated with growth hormone according to the regimen of the treatment of children with somatotropic hypophysis insufficiency. It is only when the lack of the efficacy of such treatment is observed that further diagnostics are conducted, which indicate inflammatory disease of the intestines as the origin of short stature. Overproduction of pro-inflammatory cytokines, including TNF-α, INF-γ, IL-6, IL-12, IL-17, IL-23, and IL-1β, plays a key role in the

Table I. Nutritional deficiencies in patients with inflammatory bowel diseases

| Macro- and micro-nutrient deficiencies | Nutrients                  | Percentage of CD patients with deficiencies |
|----------------------------------------|-----------------------------|---------------------------------------------|
| Hypoproteinemia and hypoalbuminemia    | Protein (albumin)           | 17.6                                        |
| Anemia                                 | Iron deficiency             | 39.2                                        |
|                                         | B₁₂ deficiency              | 18.4                                        |
|                                         | Folic acid deficiency       | 19.0                                        |
| Electrolyte and trace elements         | Zinc                        | 15.2                                        |
|                                         | Copper                      | 84.0                                        |
|                                         | Selenium                    | 82.0                                        |
| Vitamin deficiency (low serum levels)  | B₁₂ deficiency              | 18.4                                        |
|                                         | Vitamin A                   | 23.4                                        |
|                                         | Vitamin B                   | 29.0                                        |
|                                         | Vitamin C                   | 84.0                                        |
|                                         | Vitamin D                   | 17.6                                        |
|                                         | Vitamin E                   | 16.0                                        |

According to Hartman et al. [14]

Table II. Pathophysiology of growth failure in children with inflammatory bowel diseases

| Etiopathogenesis                          | Mechanism                                      |
|-------------------------------------------|------------------------------------------------|
| Energy and nutrient deficiencies          | Deficits of energy, macronutrients and micronutrients |
| Inflammation (pro-inflammatory cytokines) | Anorexigenic effect                             |
|                                          | GH-IGF-1 axis                                  |
|                                          | Bone metabolism disturbance                    |
|                                          | Catabolic effects                               |
| Disease severity and disease location     | Disease severity                               |
|                                          | Jejunal localization                            |
| Abnormal bone metabolism                  | Effect of pro-inflammatory cytokines           |
|                                          | GH-IGF-1 axis dysfunction                      |
|                                          | Calcium and vitamin D deficiency               |
|                                          | Delayed sexual maturation                      |
|                                          | Corticosteroids                                |
| Delayed onset of sexual maturation        | Hypogonadism                                   |
| Abnormal IGF-1 axis                       | Low IGF-1 and IGF-1BP                          |
| Drugs                                     | Corticosteroids                                |
|                                          | Pro-inflammatory cytokines                     |

According to Hartman et al. [14]
resistance mechanism of tissue resistance to the action of hormonal factor stimulating the growth process [16-18]. Studies on animals have documented a pivotal role of IL-6, which induces growth inhibition due to the suppression of IGF-1 secretion. In experimental studies, administering anti-IL-6 antibodies to mice provoked significant growth acceleration. It was demonstrated that in patients with Crohn’s disease the presence of genotype IL-6-174 is connected with the highest expression and production of this interleukin; hence such studies might be important in the prognosis of the course of the disease [19]. The direct effect of IL-6 on the bone system is established on the stimulation of maturation and activation of osteoclasts on one hand, and on inhibition of osteoblasts on the other, which reduces the growth plate as a final result. Independently of cytokine activity, of importance is chronic exposure to bacterial endotoxins, lipopolysaccharides (LPS) and others, which induce insensitivity to growth hormone activity.

Although chronic use of epinephric hormones during periods of exacerbation of the disease decreases its activity and for a short time stimulates growth, finally it may negatively influence the growth process by its premature termination. Exogenous hormones provoke the state of functional GH deficiency. They also have a weak influence on mucosal healing, which is currently the objective of the therapy. In the group of hormonal factors a certain importance is ascribed to disturbances in steroid hormones and thyroxin secretion, which is observed in exacerbations of inflammatory bowel disease.

Nutritional factors

The influence of nutritional factors is also complex. On one hand, these diseases are accompanied by a significant lack of appetite and restriction in food consumption. It seems that this process is dependent on the action of TNF-α, one of the most important pro-inflammatory cytokines, the overabundance of which causes quantitative and caloric restrictions due to the effect on hypothalamic nervous tracts linked with satiety and appetite. On the other hand, intestinal malabsorption, frequent diarrhea, intestinal passage disturbances, abdominal pain, surgical procedures and increased catabolism cause that even those diminished amounts of nutritional components are not fully utilized. It is worth emphasizing that energetic expenditure in children with remission phases of the disease does not differ from the caloric requirement of healthy children; therefore, efficient management of the disease is a condition of proper development. The recommended special diet is not well accepted due to its taste, especially by the youngest children. Hence, increased energetic expenditure is accompanied by diminished energetic supply. Therefore, establishment of energetic balance in the planning of nutrition of children with inflammatory disease and current supplementation of energetic losses in exacerbation periods are of significant importance. Gradually, worsening quantitative and qualitative deficiencies result in malnutrition and growth failure.

Treatment of growth disturbances in children with inflammatory bowel diseases

Many practical observations and clinical studies in children with inflammatory bowel diseases indicate a positive correlation between effective treatment and improvement of growth rate.

Biologic treatment of Crohn’s disease with anti-TNF-α antibodies is the best documented management of growth rate improvement in children. The pathogenetic mechanism is clear and is linked to inhibition of pro-inflammatory cytokine production by the group of these drugs and indirect effect on the GH/IGF-1 axis. Moreover, it is known that TNF-α may induce reduction of lifespan and death of chondrocytes. In the studies of Malik et al., in patients who responded positively to the treatment with anti-TNF-α an increase in height velocity (HV) from 2.0 cm per year to 6.4 centimeters per year was demonstrated. This process was accompanied by a statistically significant increase in specific bone alkaline phosphatase as a marker of increased osteoblastic activity. In patients who did not respond to the treatment an improvement of growth velocity was not observed [20]. Borrelli et al. also demonstrated that the effect of that treatment was significantly better if the treatment was prolonged than if it was limited to induction with three doses of the drug [21]. Biologics directly affect bone metabolism and the reabsorption process in a mechanism independent of anti-inflammatory action [9]. In the studies of Malaise et al. it was demonstrated that already after eight weeks of biologic treatment biochemical markers of bone formation (type-1 collagen C-telopeptide, type-1 procollagen, osteocalcin, specific alkaline phosphatase) were normalized in 14-51% of patients [22]. Long-term effects of such treatments are still unknown and they require further studies.

Enteral feeding may be an alternative to steroid hormones and allows clinical remission to be obtained equally effectively as steroid therapy. Nutritional treatment with elementary formulas, semi-elementary formulas and polymeric diets applied temporarily or as a nocturnal alimentation corrects nutritional deficits very effectively, has a trophic effect on the intestinal mucosa, exerts an anti-inflammatory effect and stimulates mucosal healing, which improves high velocity [23].
Such treatment allows remission to be obtained in up to 80% of children with newly diagnosed Crohn’s disease, and also is frequently effective (in 58%) in chronically ill patients in whom other forms of therapy were applied [24]. Although earlier studies on enteral nutritional therapy were encouraging and its efficacy was compared to the treatment with steroids in achieving remission, studies from recent years indicate smaller efficacy of nutritional therapy and further studies are necessary to establish its true effectiveness [25]. In certain cases enteral nutrition may be supplemented by parenteral nutrition, especially when oral nutrition is impossible or contraindicated as for example after surgical procedures. Suprarenal hormones inhibit activity of the chondrocyte growth plate, which causes deceleration of the long growth of bones and is the effect of local decrease of IGF-1 expression. The effect of steroids is, therefore, functional deficiency of growth hormone and decreased affinity of IGF-1 within the chondrocyte growth plate. This effect is observable even at a relatively low dose of prednisolone (3-5 mg/m²). Long-term effects of these drugs remain controversial. In the studies of Griffiths et al. it was demonstrated that the use of steroids causes decrease of growth rate only in the first year of treatment; however, this reduction was not statistically significant if current activity of the disease was taken into account [26]. In order to diminish potential adverse effects, alternate therapy and selective elimination of the evening administration of the drugs may be the alternative; this allows one to avoid the inhibition of nocturnal secretion of GH. In selected patients the use of budesonide may be an option which allows these adverse reactions to be limited [4]. Budesonide is a drug with small availability due to the “effect of first passage” through the liver, since only 90% of the absorbed amount of the drug is metabolized by isoenzyme CYP3A4 of cytochrome P450 to compounds with low activity.

One of the therapeutic options, especially if growth retardation is accompanied by pubertal delay, is the use of testosterone derivatives. In the studies of Mason et al. in a group of boys with inflammatory bowel disease oral or parenteral administration of this hormone caused improvement of growth velocity by more than 50% and appearance of sexual maturation in the majority of children [27].

Efficacy of immunosuppressive drugs, mainly from the thiopurine group (azathioprine, 6-mercaptopurine), is well documented in supporting remission in Crohn’s disease. The influence of such therapy on growth rate in children is not known. In a well-conducted randomized study of Markowitz et al. it was found that the growth rate in children who were treated with thiopurines from the moment of diagnosis was faster than in children treated conventionally [28]. Early introduction of drugs from this group diminishes the necessity for suprarenal hormones which delays the process of cartilage ossification and advantageously affects the final growth. A similar positive effect on remission permanence and growth process in children with Crohn’s disease as in the case of thiopurines has been demonstrated for methotrexate [29].

Zinc is one of the principal microelements, which is necessary for catalysis of about 100 various enzymes, and its deficiency in inflammatory bowel disease, and in Crohn’s disease especially, is one of the main causes of growth deterioration. Appropriate supplementation of this element decrease such risk [30].

Surgical management in children with inflammatory bowel disease is reserved for the treatment of complications. However, in several retrospective studies, in which growth rate in children with inflammatory bowel disease during the pre-pubertal period who underwent surgical local resection of the intestine due to the resistance of the disease to the treatment, has been evaluated and statistically significant acceleration of growth rate has been observed after these procedures [31-33]. These procedures caused an increase of anabolic processes, expressed as increased utilization of nitric compounds already 4 weeks after the procedure. However, in these studies long-term results of such management of the patient and its effect on the final height after puberty were not analyzed.

In the analysis of the Cochrane Database there are only a few methodologically well-conducted and documented therapeutic interventions which influence height of children with Crohn’s disease. These interventions include enteral nutrition, intestinal resections in children with disease resistant to therapy during the pre-pubertal period, and currently the most recommended therapy with anti-TNF-α antibodies [34]. In the case of ulcerative colitis there are significantly fewer such observations and they pertain only to the influence of colectomy on growth in disease resistant to treatment [35, 36].

**Summary**

Growth retardation in children with inflammatory bowel disease is an important, concerning symptom, which, especially in Crohn’s disease, may precede the diagnosis. Due to that, the disturbances of growth rate are taken into account in the Paris classification of Crohn’s disease. Pathogenesis of growth disturbances in children is complex. Early diagnosis and appropriate management of this disease with the objective of obtaining not only clinical but also endoscopic and histologic remission allows prevention of this complication. Current-
ly the most promising is biologic treatment with anti-TNF-α antibodies, which most effectively inhibits the illness of the intestine [37, 38]. Of enormous importance is constant monitoring of child development since growth inhibition may be one of the important signals indicating inefficient management [39, 40].

References
1. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17: 1314-21.
2. Turner D, Travis SP, Griffiths AM, et al.; European Crohn's and Colitis Organization; Porto IBD Working Group, European Society of Pediatric Gastroenterology, Hepatology, and Nutrition: Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011; 106: 574-88.
3. Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 2011; 17: 440-9.
4. Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 839-49.
5. Conklin LS, Oliva-Hemker M. Nutritional considerations in pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010; 4: 305-17.
6. Taminiau JA. The clinical importance of growth in children with inflammatory bowel disease: is it important to the gastroenterologist? Aliment Pharmacol Ther 2007; 26 Suppl 2: 53-6.
7. Wine E, Reif SS, Leshinsky-Silver E, et al. Pediatric Crohn’s disease and growth retardation: the role of genotype, phenotype, and disease severity. Pediatrics 2004; 114: 1281-6.
8. Kierkus J, Szymańska S, Szymańska E, et al. Mechanizmy upośledzenia wzrostania u dzieci z chorobą Leśniowskiego-Crohn na. Stand Med Pediatria 2010; 4: 597-605.
9. Paerregaard A, Uldall Urne F. Anthropometry at the time of diagnosis in Danish children with inflammatory bowel disease. Acta Paediatr 2005; 94: 1682-3.
10. Ferreira R, Almeida S. Crohn’s disease in a child: unusual presentation with severe osteoporosis. Bio Drugs 2010; 14 (24 Suppl 1): 31-3.
11. Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al. Nutritional status and growth in pediatric Crohn’s disease: a population-based study. Am J Gastroenterol 2010; 105: 1893-900.
12. Cormier K, Magee D, Bannister L, et al. Resting energy expenditure in the parenterally fed pediatric population with Crohn’s disease. J Parenter Enteral Nutr 2005; 29: 102-7.
13. Ahmed SF, Wong JS, McGrogan P. Improving growth in children with inflammatory bowel disease. Horm Res 2007; 68 Suppl 5: 117-21.
14. Hartman C, Elakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15: 2570-8.
15. Wong SC, Smyth A, McNeill E, et al. The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin Endocrinol (Oxf) 2010; 73: 220-8.
16. Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr 2006; 43: 144-55.
17. Shamir R, Phillips M, Levine A. Growth retardation in pediatric Crohn’s disease: pathogenesis and interventions. Inflamm Bowel Dis 2007; 13: 620-8.
18. MacRae VE, Wong SC, Farquharson C, Ahmed SF. Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review). Int J Mol Med 2006; 18: 1011-8.
19. Sawczmeno A, Azoou O, Paraszczuk J, et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci U S A 2005; 102: 13260-5.
20. Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011; 52: 31-7.
21. Borrelli O, Basletto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 2004; 36: 342-7.
22. Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther 2004; 20: 607-14.
23. Ballinger A. Management of growth retardation in the young patient with Crohn’s disease. Expert Opin Pharmacotherapy 2002; 3: 1-7.
24. Day AS, Whitten KE, Lemberg DA, et al. Exclusive enteral feeding as primary therapy for Crohn’s disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol 2006; 21: 1609-14.
25. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2007; 1: CD000542.
26. Griffiths AM, Nguyen P, Smith C, et al. Growth and clinical course of children with Crohn’s disease. Gut 1993; 34: 939-43.
27. Mason A, Wong SC, McGrogan P, Ahmed SF. Effect of testosterone therapy for delayed growth and puberty in boys with inflammatory bowel disease. Horm Res Paediatr 2011; 75: 8-13.
28. Markowitz J, Groncher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone therapy for delayed growth and puberty in boys with inflammatory bowel disease. J Pediatr 2011; 158: 200-5.
29. Hyams JS, Markowitz JF. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol 2007; 102: 2804-12.
30. Saper RB, Rash R. Zinc: an essential micronutrient. Am Fam Physician 2009; 79: 768-72.
31. El-Baba M, Lin CH, Klein M, Tolia V. Outcome after surgical intervention in children with chronic inflammatory bowel disease. Am Surg 1996; 62: 1014-7.
32. Sentongo TA, Stettler N, Christian A, et al. Growth after intestinal resection for Crohn’s disease in children, adolescents, and young adults. Inflamm Bowel Dis 2006; 6: 265-9.
33. Uchida K, Miki C, Inoue M, et al. Surgical intervention for neonatal and infantile-onset severe colonic Crohn’s disease: report of three cases. Dis Colon Rectum 2008; 51: 247-50.
34. Newby EA, Sawczenco A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst Rev 2005; 3: CD003873.
35. Nicholls S, Vieira MC, Majrowski WH, et al. Linear growth after colectomy for ulcerative colitis in childhood. J Pediatr Gastroenterol Nutr 1995; 21: 82-6.
36. Akobeng AK. Crohn’s disease: current treatment options. Arch Dis Child 2008; 93: 787-92.
37. Aloi M, Cucchiara S. Extradigestive manifestations of IBD in pediatrics. Eur Rev Med Pharmacol Sci 2009; 13 Suppl 1: 23-32.
38. Griffiths AM. Growth retardation in early-onset inflammatory bowel disease: should we monitor and treat these patients differently? Dig Dis 2009; 27: 404-11.
39. Levine A, Shamir R, Wine E, et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn’s disease. Am J Gastroenterol 2005; 100: 1598-604.
40. Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr 2005; 40: 262-72.